Irinotecan Kabi 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUG3 trials

Sponsors

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH, Institut De Recherches Internationales Servier IRIS, Charite Universitaetsmedizin Berlin KöR

Conditions

BRAF and Other Selected RAS/MAPK MutationsMalignancies with Documented KRASadvanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctionslocally advanced or metastatic small bowel adenocarcinomawho failed prior line of palliative chemotherpay

Phase 1

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

Not yet recruitingCTIS2025-523474-16-00

Institut De Recherches Internationales Servier IRISMalignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mutations

Target: 75Updated: 2026-04-22

Phase 2

Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma [FIRE-12]

Not yet recruitingCTIS2025-524131-39-00

Charite Universitaetsmedizin Berlin KöRlocally advanced or metastatic small bowel adenocarcinoma

Target: 112Updated: 2026-08-13

Phase 3

Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy - The Phase II/III RAMIRIS STUDY

Active, not recruitingCTIS2024-512934-14-00

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbHadvanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctions, who failed prior line of palliative chemotherpay

Start: 2016-11-07Target: 319Updated: 2025-06-23